Company: INDP
Filing Date: 2025-02-12
Form Type: S-1
Source: 0001493152-25-006068
Chunk: 175

Company: Indaptus Therapeutics, Inc.
Filing Date: 2025-02-12
Form: S-1
Chunk 175
---
 expected to vest as of September 30, 2024 |     |           | 2,487,822 |   |     | $                |  9.20 |     |             | 7.5 |     | $               |      - |

The following table summarizes the total stock-based compensation expense included in the condensed consolidated statements of operations for the periods presented:

SCHEDULE OF STOCK BASED COMPENSATION EXPENSES

|                                        |     | For the three months ended 
 September 30,              
 2024                       |    2024 |     | 2023 |    2023 |     | For the nine months ended 
 September 30,             
 2024                      |      2024 |     | 2023 |      2023 |
|:---------------------------------------|:----|:---------------------------|--------:|:----|:-----|--------:|:----|:--------------------------|----------:|:----|:-----|----------:|
| Research and development               |     | $                          | 108,447 |     |      | 200,624 |     |                           |   547,927 |     |      |   586,854 |
| General and administrative             |     |                            | 335,737 |     |      | 564,179 |     |                           | 1,453,800 |     |      | 1,633,559 |
| Total stock-based compensation expense |     | $                          | 444,184 |     |      | 764,803 |     |                           | 2,001,727 |     |      | 2,220,413 |

As of September 30, 2024, total compensation cost not yet recognized related to unvested stock options was approximately $ 0.9million and such amount is expected to be recognized over a weighted average period of 1.6years.

The Company estimates the fair value of stock options on the date of grant using the Black-Scholes option-pricing model. The Black-Scholes option-pricing model requires estimates of highly subjective assumptions, which affect the fair value of each stock option. The weighted average inputs used to measure the value of the options granted during the nine months ended September 30, 2024 are presented in the table below. The weighted average fair value of stock options granted during the nine months ended September 30, 2024 was $ 1.67per share.

SCHEDULE OF WEIGHTED